Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database (Q28481584)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication bias

0 references

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Daniel Knoepflmacher

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Lee Shapley

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

0 references

publication date

20 March 2012

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

e1001189

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

copyright license

Creative Commons CC0 License

20 March 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted, dedicated to the public domain by copyright holder

0 references

Reporting bias in medical research - a narrative review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Antidepressant drug effects and depression severity: a patient-level meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Publication bias in clinical trials due to statistical significance or direction of trial results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Publication of clinical trials supporting successful new drug applications: a literature analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Efficacy of antidepressants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Full publication of results initially presented in abstracts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

A taxpayer-funded clinical trials registry and results database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

Meta-analysis in clinical trials

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

7 April 2017

Systematic review of the empirical evidence of study publication bias and outcome reporting bias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

7 April 2017

Modified intention to treat reporting in randomised controlled trials: systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Biases in medication prescribing: the case of second-generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

The need for improved access to FDA reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Do effectiveness ("real world") studies on antipsychotics tell us the real truth?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Uncertainty in heterogeneity estimates in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Size of treatment effects and their importance to clinical research and practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Assessing Response Profiles from Incomplete Longitudinal Clinical Trial Data Under Regulatory Considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO/NIH Joint Project CAR Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Risperidone in the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

29 September 2017

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

2 June 2018

Registering clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

2 June 2018

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

2 June 2018

Risperidone: clinical safety and efficacy in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

2 June 2018

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001189

21 January 2018

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001189

21 January 2018

Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001189

21 January 2018

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001189

21 January 2018

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001189

21 January 2018

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001189

21 January 2018

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3308934

27 November 2018

Transparency at the Food and Drug Administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anchoring the BPRS: an aid to improved reliability

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22448149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PMED.1001189

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22448149%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28481584&oldid=1868026008"